2026 ICD-10-CM Diagnosis Code Q81.0Epidermolysis bullosa simplex
ICD-10-CM Codes›Q00-Q99›Q80-Q89›Q81
- Billable — Valid for Submission
- POA Exempt
- Chronic Condition
Q81.0 is a billable ICD-10-CM diagnosis code for epidermolysis bullosa simplex. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 595 through 596. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified congenital anomalies.
Code Identity
Code Classification
Present on Admission (POA)Billing
Q81.0 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Autosomal dominant epidermolysis bullosa simplex
- Autosomal recessive epidermolysis bullosa simplex
- Basal epidermolysis bullosa simplex
- Epidermolysis bullosa simplex
- Epidermolysis bullosa simplex due to BP230 deficiency
- Epidermolysis bullosa simplex due to exophilin 5 deficiency
- Epidermolysis bullosa simplex due to plakophilin deficiency
- Epidermolysis bullosa simplex herpetiformis
- Epidermolysis bullosa simplex with circinate migratory erythema
- Epidermolysis bullosa simplex with hypodontia
- Epidermolysis bullosa simplex with mottled pigmentation
- Epidermolysis bullosa simplex with muscular dystrophy
- Epidermolysis bullosa simplex with pyloric atresia
- Epidermolysis bullosa simplex, Ogna type
- Epidermolysis simplex superficialis
- Gastric atresia
- Generalized epidermolysis bullosa simplex
- Intermediate epidermolysis bullosa simplex with cardiomyopathy
- Keratoderma due to Dowling-Meara type epidermolysis bullosa simplex
- KRT14 related epidermolysis bullosa simplex
- Lethal acantholytic erosive disorder
- Lethal autosomal recessive epidermolysis bullosa simplex
- Pyloric atresia
- Suprabasal epidermolysis bullosa simplex
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Type 1 Excludes
- Cockayne's syndrome Q87.19
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- bullosa (congenital) - Q81.9
- simplex - Q81.0
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Epidermolysis
- bullosa (congenital)
- simplex
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Epidermolysis Bullosa Simplex
a form of epidermolysis bullosa characterized by serous bullae that heal without scarring. mutations in the genes that encode keratin-5 and keratin-14 have been associated with several subtypes of epidermolysis bullosa simplex.Epidermolysis Bullosa Simplex
a genetic skin disorder caused by mutations in the krt5 and krt14 genes. it is characterized by the formation of blisters and increased fragility of the skin.Intermediate Epidermolysis Bullosa Simplex with Cardiomyopathy
an autosomal dominant condition caused by mutation(s) in the klhl24 gene, encoding kelch-like protein 24. it is characterized by epidermolysis bullosa and dilated cardiomyopathy.KRT5 wt Allele|CK5|DDD|DDD1|EBS2|Epidermolysis Bullosa Simplex 2 Dowling-Meara/Kobner/Weber-Cockayne Types Gene|K5|KRT5A|Keratin 5 (Epidermolysis Bullosa Simplex, Dowling-Meara/Kobner/Weber-Cockayne Types) Gene|Keratin 5 wt Allele|Keratin 5, Type II Gene
human krt5 wild-type allele is located in the vicinity of 12q13.13 and is approximately 6 kb in length. this allele, which encodes keratin, type ii cytoskeletal 5 protein, plays a role in the formation of the epidermis. mutation of the gene is associated with dowling-degos disease and several subtypes of epidermolysis bullosa simplex.Plectin|Epidermolysis Bullosa Simplex 1 (Ogna)|Hemidesmosomal Protein 1|Plectin 1, Intermediate Filament Binding Protein 500kDa|Plectin-1
plectin (4684 aa, ~53 kda) is encoded by the human plec gene. this protein plays a role in linking intermediate filaments to desmosomes or hemidesmosomes.
Patient EducationClinical
Skin Conditions
Your skin is your body's largest organ. It covers the entire outside of your body. There are many ways that your skin protects your body and helps keep you healthy. For example, it:
The full article covers:
- What does your skin do?
- What problems and conditions can affect your skin?
- How can I keep my skin healthy?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert Q81.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About Q81.0Overview
Is Q81.0 (Epidermolysis bullosa) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report epidermolysis bullosa simplex on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does Q81.0 group to?
When epidermolysis bullosa simplex is the principal diagnosis on an inpatient stay, it groups to MS-DRG 595, 596, with relative weights from 1.0825 to 2.1207 depending on complications. Higher weights mean higher Medicare reimbursement.
Is Q81.0 exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for epidermolysis bullosa simplex on inpatient claims.
What is the ICD-9 equivalent of Q81.0?
Under the General Equivalence Mappings, epidermolysis bullosa simplex converts to ICD-9-CM 757.39 (skin anomaly NEC). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
